Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1999-12-22
2000-12-26
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514192, 5142312, 514470, 514565, 514668, A61K 3800, A61K 3143, A61K 31535, A61K 3134, A61K 31195, A61K 3113
Patent
active
061659754
ABSTRACT:
A method of treatment, in an organism, of a vascular condition, comprising administration of at least one agent at a level which enhances NO and which does not appreciably alter normal systemic vascular tone in said organism. At least one agent is an NO donor selected from the group consisting of glyceryl trinitrate, isosorbide 5-mononitrate, isosorbide dinitrate, pentaerythritol tetranitrate, erythrityl tetranitrate, sodium nitroprusside, 3-morpholinosydnonimine molsidomine, S-nitroso-N-acetylpenicillamine, S-nitrosoglutathione, and N-hydroxy-L-arginine.
REFERENCES:
patent: 5059603 (1991-10-01), Rubin
patent: 5284828 (1994-02-01), Hemmi et al.
patent: 5338726 (1994-08-01), Shiosaki et al.
patent: 5378715 (1995-01-01), Stein et al.
patent: 5382569 (1995-01-01), Cody et al.
Mordenti, J., "Man versus Beast: Pharmacokinetic Scaling in Mammals," Journal of Pharmaceutical Sciences, Nov. 1986. 75(11):1028-1040.
Palmer, R.M. et al., "Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor," Nature, Jun. 1987. 327:524-526.
Berkow, R., A. Fletcher, eds. Merck Manual of Diagnosis and Therapy. Rahway, N.J.: Merck Sharp & Dohme Research Laboratories, 1987. p. 400.
Bennett, B.M. et al., "Effect of In Vitro Organic Nitrate Tolerance on Relaxation, Cyclic GMP Accumulation, and Guanylate Cyclase Activation By Glyceryl Trinitrate and the Enantiomers of Isoidide Dinitrate," Circulation Research, Oct. 1988. 63(4):693-701.
Garg, U.C. and A. Hassid, "Nitric Oxide-generating Vasodilators and 8-Bromo-Cyclic Guanosine Monophosphate Inhibit Mitogenesis and Proliferation of Cultured Rat Vascular Smooth Muscle Cells," J. Clin. Invest., May 1989. 83:1774-1777.
Ignarro, L.J. et al., "Nitric Oxide And Cyclic GMP Formation Upon Electrical Field Stimulation Cause Relaxation Of Corpus Cavernosum Smooth Muscle," Biochemical and Biophysical Research Communications, Jul. 1990. 170(2):843-850.
Garg, U.C. and A. Hassid, "Nitric Oxide Decreases Cytosolic Free Calcium in Balb/c 3T3 Fibroblasts by a Cyclic GMP-independent Mechanism," The Journal of Biological Chemistry, Jan. 1991. 266(1):9-11.
Heaton, J.P. et al., "The Characterization Of A Bio-Assay of Erectile Function in a Rat Model," The Journal of Urology, May 1991. 145:1099-1102.
Tolins, J.P. et al., "Role of Endothelium-Derived Relaxing Factor in Regulation of Vascular Tone and Remodeling. Update on Humoral Regulation of Vascular Tone," Hypertension, Jun. 1991. 17(6):909-913.
Johnson, R.A. and R.H. Freeman, "Sustained Hypertension in the Rat Induced by Chronic Blockade of Nitric Oxide Production," American Journal of Hypertension, Inc., Dec. 1992. 5(12):919-922.
Farhy, R.D. et al., "Role of Kinins and Nitric Oxide in the Effects of Angiotensin Converting Enzyme Inhibitors on Neointima Formation," Circulation Research, Jun. 1993. 72(60:1202-1208.
Brock, G. et al., "Intracavernous Sodium Nitroprusside: Inappropriate Impotence Treatment," The Journal of Urology, Sep. 1993. 150:864-867.
Feldman, H.A. et al., "Impotence and Its Medical and Psychosocial Correlates: Results of the Massachusetts Male Aging Study," The Journal of Urology, Jan. 1994. 151:54-59.
Heaton, J.P. et al., "Recovery ff Erectile Function by the Oral Administration of Apomorphine," Urology, Feb. 1995. 45(2):200-206.
Richard, V. et al., "In Vivo Evidence of an Endothelin-Induced Vasopressor Tone After Inhibition of Nitric Oxide Synthesis in Rats," Circulation, Feb. 1995. 91(3):771-775.
Sun, J.X. et al., "Comparative Pharmacokinetics and Bioavailability of Nitroglycerin and its Metabolites from Transderm-Nitro, Nitrodisc, and Nitro-Dur II Systems Using a Stable-Isotope Technique," J. Clin. Pharmacol., 1995. 35:390-397.
Banting, J.D. et al., "Acute hypertension after nitric oxide synthase inhibition is mediated primarily by increased endothelin vasoconstriction," Journal of Hypertension, 1996. 14(8):975-981.
Adams, M.A. et al., "Vascular control mechanisms in penile erection: phylogeny and the inevitability of multiple and overlapping systems," International Journal of Impotence Research, 1997. 9:85-91.
King, R.C., et al. "Low-dose sodium nitroprusside reduces pulmonary reperfusion injury," Forty-Third Annual Meeting of the Southern Thoracic Surgical Association, 1997. pp. 1398-1404. (Printed article from the internet 11 pages.).
McNay, John. "Pharmacology of the Renal Circulation." The American Journal of Medicine, vol. 62, Apr. 1977, pp. 507-513.
Heaton, Jeremy. "Preliminary Studies, In Rabbit Penile Cavernosal Tissue, of the Role of Synthetic Nitrovasodilators in Erectile Response." Current Therapeutic Research, vol. 45(2), Feb. 1989, pp. 278-284.
Ahmad, S. "Scleroderma and Impotence: Response to Nitroglycerin Applied to the Fingers and Penis." Letter, Dec. 1990, p. 1495.
Gardiner, S. M., et al. "Regional and cardiac haemodynamic responses to glyceryl trinitrate, acetylcholine, bradykinin and endothelin-1 in conscious rats: effects of NG-nitro-L-arginine methyl ester." Br. Journal of Pharmacology, vol. 101, 1990, pp. 632-639.
Stief, Christian, et al. "Preliminary Results with the Nitric Oxide Donor Linsidomine Chlorhydrate in the Treatment of Human Erectile Dysfunction." The Journal of Urology, vol. 148, Nov. 1992, pp. 1437-1440.
Anderson, Douglas Jr., et al. "Topical Nitrate Treatment of Impotence." The Annals of Pharmacotherapy, vol. 27, Oct. 1993, Abstract on pp. 1203-1205.
Hellstrom, Wayne, et al. "Penile Erection in the Primate: Induction with Nitric-Oxide Donors." The Journal of Urology, vol. 151, Jun. 1994, pp. 1723-1727.
Kirkeby, H. J., et al. "Role of the L-arginine
itric oxide pathway in relaxation of isolated human penile cavernous tissue and circumflex veins." Acta Physiol. Scand., vol. 149, 1995, pp. 385-932.
Kurokawa, Hiroshi. "Portal and systemic hemodynamic responses to a very low dose of nitroglycerin in cirrhotic patients with portal hypertension." J. Nippon Med. Sch., vol. 62(1), 1995, pp. 2 -12.
Trigo-Rocha, Flavio, et al. "Sodium nitroprusside: physiologic effects as a nitric oxide donor in three species." Int. Journal Impotence Research, vol. 7, 1995, pp. 49-56.
Vargas, Felix, et al. "Endothelium-Dependent and Endothelium-Independent Vasodilation in Hyperthyroid and Hypothyroid Rats." Pharmacology, vol. 51, 1995, pp. 308-314.
Tarhan, Faith, et al. "Effect of Intracavernosal Sodium Nitroprusside in Impotence." Urology International, vol. 56, 1996, pp. 211-214.
Vargas, Felix, et al. "Vascular reactivity and flow-pressure curve in isolated kidneys from rats with N-nitro-L-arginine methyl ester-induced hypertension."Journal of Hypertension, vol 14(3), 31996, pp. 373-379.
Jeremy, J. Y., et al. "Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and Papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro." British Journal of Urology, vol. 79, 1997, pp. 958-963.
King, Robert, et al. "Low-Dose Sodium Nitroprusside Reduces Pulmonary Reperfusion Injury." Annals of Thoracic Surgery, vol. 63, 1997, pp. 1398-1404.
Martel, A. M., et al. "Sildenafil." Drugs of the Future, vol. 22(2), 1997, pp. 138-143.
Renganathan, R., et al. "Comparison of transdermal nitroglycerin and intracavernous injection of papaverine in the treatment of erectile dysfunction in patients with spinal cord lesions." Spinal Cord, vol. 35, 1997, pp. 99-103.
Vargas, Felix, et al. "Abnormal Renal Vascular Reactivity to Acetylcholine and Nitroprusside in Aging Rats." General Pharmacology, vol. 28(1) 1997, pp. 133-137.
Adams Michael A.
Banting James D.
Heaton Jeremy P. W.
Henley III Raymond
Janssen Jerry F.
Queen's University at Kingston
Steeg Carol Miernicki
Wilhelm Thomas D.
LandOfFree
Microdose therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Microdose therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Microdose therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-994862